We report a case of metastatic castration-resistant prostate cancer, who received prior treatment with docetaxel and was then given cabazitaxel as salvage therapy. The patient was monitored by prostate-specific antige...We report a case of metastatic castration-resistant prostate cancer, who received prior treatment with docetaxel and was then given cabazitaxel as salvage therapy. The patient was monitored by prostate-specific antigen doubling time and prostate-specific antigen absolute value. The prostate-specific antigen doubling time was found to be a good response predictor in the patient.展开更多
Docetaxel-based chemotherapy remains the first-line treatment for patients with metastatic castration-resistant prostate cancer （mCRPC） in China; however, the prognostic factors associated with effects in these pati...Docetaxel-based chemotherapy remains the first-line treatment for patients with metastatic castration-resistant prostate cancer （mCRPC） in China; however, the prognostic factors associated with effects in these patients are still controversial. In this study, we retrospectively reviewed the data from 71 eligible Chinese patients who received docetaxel chemotherapy from 2009 to 2016 in our hospital and experienced a reduction of prostate-specific antigen （PSA） level 〉50% during the treatment and investigated the potential role of time to nadir （TTN） of PSA. TTN was defined as the time from start of chemotherapy to the nadir of PSA level during the treatment. Multivariable Cox regression models and Kaplan-Meier analysis were used to predict overall survival （OS）. In these patients, the median of TTN was 17 weeks. Patients with TTN ≥17 weeks had a longer response time to chemotherapy compared to TTN 〈17 weeks （42.83 vs 21.50 weeks, P 〈 0.001）. The time to PSA progression in patients with TTN ：〉17 weeks was 11.44 weeks compared to 5.63 weeks when TTN was 〈17 weeks. We found several factors to be associated with OS, including TTN （hazard ratio [HR]. 3.937, 95% confidence interval [CI]： 1.502-10.309, P = 0.005）, PSA level at the diagnosis of cancer （HR： 4,337, 95% CI： 1.616-11.645, P= 0.004）, duration of initial androgen deprivation therapy （HR： 2.982, 95% CI： 1.104-8.045, P= 0.031）, neutrophil-to-lymphocyte ratio （HR： 3.963, 95% CI： 1.380-11.384, P = 0.011）, and total PSA response （Class 1 [〈0 response] compared to Class 2 [0-50% response], HR： 3.978, 95% CI： 1.278-12.387, P = 0.017）. In conclusion, TTN of PSA remains an important prognostic marker in predicting therapeutic outcome in Chinese population who receive chemotherapy for mCRPC and have 〉50% PSA remission.展开更多
目的:探讨经直肠超声造影(contrast-enhanced transrectal ultrasound)时间-强度曲线(time-intensity curve,TIC)参数评估前列腺癌(prostate cancer,PCa)患者对新辅助内分泌治疗(neoadjuvant hormonal therapy,NHT)的反应程度。方法:纳...目的:探讨经直肠超声造影(contrast-enhanced transrectal ultrasound)时间-强度曲线(time-intensity curve,TIC)参数评估前列腺癌(prostate cancer,PCa)患者对新辅助内分泌治疗(neoadjuvant hormonal therapy,NHT)的反应程度。方法:纳入27例接受NHT的PCa患者的临床资料,根据术后病理学检查结果分为有效组(n=16)和无效组(n=11)。对比两组患者临床病理学特征、治疗前后血清前列腺特异性抗原(prostate-specific antigen,PSA)和CETRUS检查指标及其变化率,以筛选与NHT反应性有关的潜在指标。进一步采用相关性分析评价其在评估患者对NHT反应方面的价值。结果:有效组和无效组在临床病理学特征、治疗前的血清PSA和C E T R U S检查指标方面的差异无统计学意义(均P>0.05)。治疗后,仅有效组的TIC曲线下面积(area under curve,AUC)低于无效组(560 dB·s vs 710 dB·s),其变化率大于无效组(-27.1%vs-5.3%)(均P<0.05)。相关性分析显示AUC变化率与组织学反应评分之间的相关性略高于治疗后AUC(r为-0.690 vs-0.630)。结论:CETRUS TIC参数中,NHT后的AUC及其变化率在评估PCa患者对NHT反应方面具有较好的价值。其中,AUC变化率可能与治疗反应程度更相关。展开更多
文摘We report a case of metastatic castration-resistant prostate cancer, who received prior treatment with docetaxel and was then given cabazitaxel as salvage therapy. The patient was monitored by prostate-specific antigen doubling time and prostate-specific antigen absolute value. The prostate-specific antigen doubling time was found to be a good response predictor in the patient.
基金This study was partially supported by the National Natural Science Foundation of China （NSFC 81202014 to KJW, NSFC 81130041 to DLH） and the Fundamental Research Funds for the Central Universities （to KIW）.
文摘Docetaxel-based chemotherapy remains the first-line treatment for patients with metastatic castration-resistant prostate cancer （mCRPC） in China; however, the prognostic factors associated with effects in these patients are still controversial. In this study, we retrospectively reviewed the data from 71 eligible Chinese patients who received docetaxel chemotherapy from 2009 to 2016 in our hospital and experienced a reduction of prostate-specific antigen （PSA） level 〉50% during the treatment and investigated the potential role of time to nadir （TTN） of PSA. TTN was defined as the time from start of chemotherapy to the nadir of PSA level during the treatment. Multivariable Cox regression models and Kaplan-Meier analysis were used to predict overall survival （OS）. In these patients, the median of TTN was 17 weeks. Patients with TTN ≥17 weeks had a longer response time to chemotherapy compared to TTN 〈17 weeks （42.83 vs 21.50 weeks, P 〈 0.001）. The time to PSA progression in patients with TTN ：〉17 weeks was 11.44 weeks compared to 5.63 weeks when TTN was 〈17 weeks. We found several factors to be associated with OS, including TTN （hazard ratio [HR]. 3.937, 95% confidence interval [CI]： 1.502-10.309, P = 0.005）, PSA level at the diagnosis of cancer （HR： 4,337, 95% CI： 1.616-11.645, P= 0.004）, duration of initial androgen deprivation therapy （HR： 2.982, 95% CI： 1.104-8.045, P= 0.031）, neutrophil-to-lymphocyte ratio （HR： 3.963, 95% CI： 1.380-11.384, P = 0.011）, and total PSA response （Class 1 [〈0 response] compared to Class 2 [0-50% response], HR： 3.978, 95% CI： 1.278-12.387, P = 0.017）. In conclusion, TTN of PSA remains an important prognostic marker in predicting therapeutic outcome in Chinese population who receive chemotherapy for mCRPC and have 〉50% PSA remission.
文摘目的:探讨经直肠超声造影(contrast-enhanced transrectal ultrasound)时间-强度曲线(time-intensity curve,TIC)参数评估前列腺癌(prostate cancer,PCa)患者对新辅助内分泌治疗(neoadjuvant hormonal therapy,NHT)的反应程度。方法:纳入27例接受NHT的PCa患者的临床资料,根据术后病理学检查结果分为有效组(n=16)和无效组(n=11)。对比两组患者临床病理学特征、治疗前后血清前列腺特异性抗原(prostate-specific antigen,PSA)和CETRUS检查指标及其变化率,以筛选与NHT反应性有关的潜在指标。进一步采用相关性分析评价其在评估患者对NHT反应方面的价值。结果:有效组和无效组在临床病理学特征、治疗前的血清PSA和C E T R U S检查指标方面的差异无统计学意义(均P>0.05)。治疗后,仅有效组的TIC曲线下面积(area under curve,AUC)低于无效组(560 dB·s vs 710 dB·s),其变化率大于无效组(-27.1%vs-5.3%)(均P<0.05)。相关性分析显示AUC变化率与组织学反应评分之间的相关性略高于治疗后AUC(r为-0.690 vs-0.630)。结论:CETRUS TIC参数中,NHT后的AUC及其变化率在评估PCa患者对NHT反应方面具有较好的价值。其中,AUC变化率可能与治疗反应程度更相关。
